Company Overview - Tempus AI, Inc. (NASDAQ:TEM) develops technology that organizes and analyzes large amounts of clinical and molecular data to help doctors personalize patient care [2] - The company's platform utilizes AI for diagnostic tests, matching patients with clinical trials, and assisting pharmaceutical companies in discovering new cancer treatments [2] Market Performance - The stock of Tempus AI is down nearly 6% from the day Jim Cramer made comments about the company [4] - Cramer expressed skepticism about investing in Tempus AI, stating it is "losing money hand over fist" and recommended focusing on other AI stocks like NVIDIA instead [2][4] Investment Sentiment - There is a belief that while Tempus AI has potential, other AI stocks may offer greater upside potential and carry less downside risk [5] - The article suggests that investors looking for undervalued AI stocks should consider alternatives that may benefit from current market trends [5]